Kalaris Therapeutics Inc (KLRS)
$2.36-5.60%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $44M
- Beta
- 0.21
- P/E (TTM)
- -1.32
- Short % float
- 8.26%
- Days to cover
- 4.6
- SI change
- +4.3%
- 1W
- -12.59%
- 1M
- -28.48%
- vs SPY 1W
- -13.75%
- vs SPY 1M
- -31.48%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on KLRS?
- LOPJLB’s latest quantitative signal on Kalaris Therapeutics Inc (KLRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is KLRS in?
- Kalaris Therapeutics Inc (KLRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Kalaris Therapeutics Inc (KLRS) do?
- Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular reti…